Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (RELAX-AHF-ASIA)

12. června 2019 aktualizováno: Novartis Pharmaceuticals

A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients

The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.

Přehled studie

Postavení

Ukončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

876

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Filipíny
      • Makati City, Filipíny, 1229
        • Novartis Investigative Site
      • Manila, Filipíny, 1003
        • Novartis Investigative Site
      • Pasig City, Filipíny, 1605
        • Novartis Investigative Site
      • Quezon City, Filipíny, 1102
        • Novartis Investigative Site
      • Quezon City, Filipíny, 1113
        • Novartis Investigative Site
      • San Juan City, Filipíny, 1500
        • Novartis Investigative Site
    • Manila
      • Quezon City, Manila, Filipíny, 1100
        • Novartis Investigative Site
    • Metro Manila
      • Manila, Metro Manila, Filipíny, 1000
        • Novartis Investigative Site
  • Indie
      • Rajasthan, Indie, 334003
        • Novartis Investigative Site
    • Delhi
      • New Delhi, Delhi, Indie, 110029
        • Novartis Investigative Site
    • Gujarat
      • Ahmedabad, Gujarat, Indie, 380054
        • Novartis Investigative Site
      • Vadodara, Gujarat, Indie, 390022
        • Novartis Investigative Site
    • Maharashtra
      • Nagpur, Maharashtra, Indie, 440010
        • Novartis Investigative Site
      • Nagpur, Maharashtra, Indie, 440012
        • Novartis Investigative Site
    • Tamil Nadu
      • Chennai, Tamil Nadu, Indie, 600101
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Indie, 500082
        • Novartis Investigative Site
  • Japonsko
      • Osaka, Japonsko, 534-0021
        • Novartis Investigative Site
      • Saitama, Japonsko, 330 8503
        • Novartis Investigative Site
    • Aichi
      • Nagakute-city, Aichi, Japonsko, 480-1195
        • Novartis Investigative Site
      • Seto-city, Aichi, Japonsko, 489-8642
        • Novartis Investigative Site
    • Chiba
      • Kamogawa-city, Chiba, Japonsko, 2968602
        • Novartis Investigative Site
    • Ehime
      • Saijo-city, Ehime, Japonsko, 793-0027
        • Novartis Investigative Site
    • Fukuka
      • Chikushino-city, Fukuka, Japonsko, 818-8516
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka-city, Fukuoka, Japonsko, 810-0001
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japonsko, 811-0213
        • Novartis Investigative Site
      • Fukuoka-city, Fukuoka, Japonsko, 815-8588
        • Novartis Investigative Site
      • Iizuka-city, Fukuoka, Japonsko, 820-8505
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japonsko, 830-8543
        • Novartis Investigative Site
      • Kurume-city, Fukuoka, Japonsko, 830-8577
        • Novartis Investigative Site
    • Gifu
      • Ogaki-city, Gifu, Japonsko, 503-8502
        • Novartis Investigative Site
    • Hokkaido
      • Kushiro-city, Hokkaido, Japonsko, 085-0062
        • Novartis Investigative Site
      • Sapporo-city, Hokkaido, Japonsko, 006-8555
        • Novartis Investigative Site
    • Hyogo
      • Amagasaki city, Hyogo, Japonsko, 660 8550
        • Novartis Investigative Site
      • Kobe-City, Hyogo, Japonsko, 654-0155
        • Novartis Investigative Site
    • Ibaraki
      • Mito-city, Ibaraki, Japonsko, 311-4198
        • Novartis Investigative Site
    • Ishikawa
      • Kanazawa, Ishikawa, Japonsko, 920 8650
        • Novartis Investigative Site
    • Kagawa
      • Kanonji-city, Kagawa, Japonsko, 769-1695
        • Novartis Investigative Site
      • Takamatsu city, Kagawa, Japonsko, 760 8557
        • Novartis Investigative Site
    • Kanagawa
      • Kawasaki-city, Kanagawa, Japonsko, 211-8533
        • Novartis Investigative Site
      • Yokohama city, Kanagawa, Japonsko, 232 0024
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japonsko, 236 0051
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japonsko, 227-8501
        • Novartis Investigative Site
      • Yokohama-city, Kanagawa, Japonsko, 231-8682
        • Novartis Investigative Site
    • Kochi
      • Kochi city, Kochi, Japonsko, 781 8555
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto-city, Kumamoto, Japonsko, 861-4193
        • Novartis Investigative Site
      • Yatsushiro-city, Kumamoto, Japonsko, 866-8660
        • Novartis Investigative Site
    • Kyoto
      • Kyoto-city, Kyoto, Japonsko, 607-8062
        • Novartis Investigative Site
      • Uji-city, Kyoto, Japonsko, 611-0042
        • Novartis Investigative Site
    • Miyagi
      • Sendai-city, Miyagi, Japonsko, 981-3133
        • Novartis Investigative Site
    • Nagano
      • Nakano-city, Nagano, Japonsko, 383-8505
        • Novartis Investigative Site
      • Saku-city, Nagano, Japonsko, 3850051
        • Novartis Investigative Site
      • Ueda-city, Nagano, Japonsko, 386-8610
        • Novartis Investigative Site
    • Niigata
      • Niigata-city, Niigata, Japonsko, 950-1197
        • Novartis Investigative Site
    • Osaka
      • Osaka-city, Osaka, Japonsko, 540-0006
        • Novartis Investigative Site
    • Saitama
      • Kawaguchi-city, Saitama, Japonsko, 333-0842
        • Novartis Investigative Site
      • Sayama-city, Saitama, Japonsko, 350-1323
        • Novartis Investigative Site
      • Wako-city, Saitama, Japonsko, 351-0102
        • Novartis Investigative Site
    • Shiga
      • Kusatsu city, Shiga, Japonsko, 525 8585
        • Novartis Investigative Site
    • Shizuoka
      • Hamamatsu-city, Shizuoka, Japonsko, 430-8558
        • Novartis Investigative Site
      • Kakegawa-city, Shizuoka, Japonsko, 436-8555
        • Novartis Investigative Site
    • Tokyo
      • Akishima-city, Tokyo, Japonsko, 196-0003
        • Novartis Investigative Site
      • Chuo ku, Tokyo, Japonsko, 104-8560
        • Novartis Investigative Site
      • Hachioji-city, Tokyo, Japonsko, 192-0918
        • Novartis Investigative Site
      • Itabashi-ku, Tokyo, Japonsko, 173-8610
        • Novartis Investigative Site
      • Musashino-city, Tokyo, Japonsko, 180-8610
        • Novartis Investigative Site
      • Shinagawa ku, Tokyo, Japonsko, 141 8625
        • Novartis Investigative Site
      • Shinagawa-ku, Tokyo, Japonsko, 142-8666
        • Novartis Investigative Site
    • Wakayama
      • Tanabe-city, Wakayama, Japonsko, 646-8558
        • Novartis Investigative Site
  • Jordán
      • Amman, Jordán, 11183
        • Novartis Investigative Site
      • Amman, Jordán, 11184
        • Novartis Investigative Site
    • JOR
      • Amman, JOR, Jordán, 11152
        • Novartis Investigative Site
  • Korejská republika
      • Busan, Korejská republika, 602739
        • Novartis Investigative Site
      • Gwangju, Korejská republika, 61469
        • Novartis Investigative Site
      • Incheon, Korejská republika, 405 760
        • Novartis Investigative Site
      • Seoul, Korejská republika, 03080
        • Novartis Investigative Site
      • Seoul, Korejská republika, 03722
        • Novartis Investigative Site
      • Seoul, Korejská republika, 02841
        • Novartis Investigative Site
    • Bucheon Si
      • Gyeonggi do, Bucheon Si, Korejská republika, 422-711
        • Novartis Investigative Site
    • Chungcheongbuk Do
      • Cheongju si, Chungcheongbuk Do, Korejská republika, 28644
        • Novartis Investigative Site
    • Gangwon-do
      • Wonju, Gangwon-do, Korejská republika, 26427
        • Novartis Investigative Site
    • Gyeonggi Do
      • Bundang Gu, Gyeonggi Do, Korejská republika, 13620
        • Novartis Investigative Site
    • Korea
      • Seoul, Korea, Korejská republika, 05505
        • Novartis Investigative Site
      • Seoul, Korea, Korejská republika, 06351
        • Novartis Investigative Site
      • Seoul, Korea, Korejská republika, 08308
        • Novartis Investigative Site
    • Seocho Gu
      • Seoul, Seocho Gu, Korejská republika, 06591
        • Novartis Investigative Site
  • Libanon
      • Ashrafieh, Libanon, 166830
        • Novartis Investigative Site
      • Beirut, Libanon, 1107 2020
        • Novartis Investigative Site
      • Beirut, Libanon
        • Novartis Investigative Site
      • Hazmieh, Libanon, 470
        • Novartis Investigative Site
  • Malajsie
      • Kuala Lumpur, Malajsie, 59100
        • Novartis Investigative Site
      • Kuala Lumpur, Malajsie, 50400
        • Novartis Investigative Site
    • MYS
      • Kuala Lumpur, MYS, Malajsie, 56000
        • Novartis Investigative Site
    • Sabah
      • Kota Kinabalu, Sabah, Malajsie, 88300
        • Novartis Investigative Site
    • Sarawak
      • Kuching, Sarawak, Malajsie, 94300
        • Novartis Investigative Site
    • Selangor Darul Ehsan
      • Kuala Lumpur, Selangor Darul Ehsan, Malajsie, 43000
        • Novartis Investigative Site
      • Sungai Buloh, Selangor Darul Ehsan, Malajsie, 47000
        • Novartis Investigative Site
  • Singapur
      • Singapore, Singapur, 169609
        • Novartis Investigative Site
      • Singapore, Singapur, 117549
        • Novartis Investigative Site
  • Tchaj-wan
      • Changhua, Tchaj-wan, 50006
        • Novartis Investigative Site
      • Kaohsiung, Tchaj-wan, 80756
        • Novartis Investigative Site
      • Kaohsiung City, Tchaj-wan, 83301
        • Novartis Investigative Site
      • New Taipei, Tchaj-wan, 22060
        • Novartis Investigative Site
      • Taichung, Tchaj-wan, 40447
        • Novartis Investigative Site
      • Taipei, Tchaj-wan, 10002
        • Novartis Investigative Site
      • Taipei, Tchaj-wan, 11217
        • Novartis Investigative Site
      • Taipei, Tchaj-wan, 10449
        • Novartis Investigative Site
      • Taoyuan, Tchaj-wan, 33305
        • Novartis Investigative Site
      • Yilan, Tchaj-wan, 26058
        • Novartis Investigative Site
  • Thajsko
      • Bangkok, Thajsko, 10330
        • Novartis Investigative Site
      • Bangkok, Thajsko, 10700
        • Novartis Investigative Site
      • Bangkok, Thajsko, 10400
        • Novartis Investigative Site
      • Chiang Mai, Thajsko, 50200
        • Novartis Investigative Site
      • Muang, Thajsko, 40002
        • Novartis Investigative Site
    • Hat Yai
      • Songkhla, Hat Yai, Thajsko, 90110
        • Novartis Investigative Site
  • Čína
      • Beijing, Čína, 100050
        • Novartis Investigative Site
      • Chongqing, Čína, 400037
        • Novartis Investigative Site
      • Shanghai City, Čína
        • Novartis Investigative Site
    • Beijing
      • Beijing, Beijing, Čína, 100039
        • Novartis Investigative Site
      • Beijing, Beijing, Čína, 100037
        • Novartis Investigative Site
    • Gansu
      • Lanzhou, Gansu, Čína, 730030
        • Novartis Investigative Site
    • Guangdong
      • Guangzhou, Guangdong, Čína, 51000
        • Novartis Investigative Site
      • Guangzhou, Guangdong, Čína, 510515
        • Novartis Investigative Site
    • Jiangsu
      • Suzhou, Jiangsu, Čína, 215006
        • Novartis Investigative Site
      • Yangzhou, Jiangsu, Čína
        • Novartis Investigative Site
    • Liaoning
      • Shenyang, Liaoning, Čína, 110000
        • Novartis Investigative Site
      • Shenyang, Liaoning, Čína, 110003
        • Novartis Investigative Site
    • Shanghai
      • Jinshan, Shanghai, Čína, 201508
        • Novartis Investigative Site
      • Shanghai, Shanghai, Čína, 200032
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, Čína, 710061
        • Novartis Investigative Site
    • Tianjin
      • Tianjin, Tianjin, Čína, 300121
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, Čína, 310013
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, Čína, 325000
        • Novartis Investigative Site

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Male or female ≥ 18 years of age, with body weight ≤160 kg

  • Hospitalized for AHF; AHF is defined as including all of the following measured at any time between presentation (including the emergency department and outpatient clinic) and at the end of screening:

    • Persistent dyspnea at rest or with minimal exertion at screening and at the time of randomization
    • Pulmonary congestion on chest radiograph
    • Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL
  • Systolic BP ≥125 mmHg at the start and at the end of screening
  • Able to be randomized within 16 hours from presentation to the hospital, including the emergency department and outpatient clinic
  • Received intravenous furosemide of at least 40 mg total (or equivalent) at any time between presentation (this includes outpatient clinic, ambulance, or hospital including emergency department) and the start of screening for the study for the treatment of the current acute HF episode
  • Renal impairment defined as an estimate glomerular filtration rate using the between presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the Modification of Diet in Renal Disease formula (or modified sMDRD formula according to specific ethnic groups and local practice guidelines).

Exclusion Criteria:

  • Dyspnea primarily due to non-cardiac causes
  • Temperature >38.5°C (oral or equivalent), sepsis, active and clinically significant infection requiring IV anti-microbial treatment or known presence or evidence of Human Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings, including laboratory results obtained during screening period).

  • Clinical evidence of acute coronary syndrome currently or within 30 days prior to enrollment

    *Patients with systolic blood pressure >180 mmHg at the end of screening

  • AHF due to significant arrhythmias, which include any of the following: sustained ventricular tachycardia, bradycardia with sustained ventricular rate <45 beats per minute, or atrial fibrillation/flutter with sustained ventricular response of >130 beats per minute

  • Hepatic disease unrelated to Heart Failure etiology and as determined by any one of the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin > 1.5 X ULN at screening or history of hepatic encephalopathy, esophageal varices, or portacaval shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B (presence of hepatitis B surface antigen production: positive HBsAg), or chronic Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis C viral RNA, based on history and/or clinical findings, including laboratory results obtained during screening period).

    *Significant uncorrected left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area <1.0 cm2 or mean gradient >50 mmHg on prior or current echocardiogram), and severe mitral stenosis

  • History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past year with a life expectancy less than 1 year

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Čtyřnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Komparátor placeba: Placebo
Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.
Lék: Placebo
Intravenózní infuze
Jiný: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Experimentální: Serelaxin
Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.
Jiný: Standard of CareTherapy
This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
Lék: Serelaxin
Intravenózní infuze

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.
Časové okno: through day 5
The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.
through day 5

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Time to WHF
Časové okno: Through Day 5
Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).
Through Day 5
Time to CV Death
Časové okno: Through Day 180
analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).
Through Day 180
Time to All-cause Death
Časové okno: Through Day 180
Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).
Through Day 180
Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days
Časové okno: Through Day 5
Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale
Through Day 5
Dyspnea by VAS-AUC Changes
Časové okno: Through Day 5
Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours
Through Day 5
Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization
Časové okno: Up to day 30
Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day
Up to day 30
Renal Dysfunction and Prevention of Worsening of Renal Function
Časové okno: Through Day 5
number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5
Through Day 5
Time to Re-hospitalization Due to Heart Failure and Renal Impairment
Časové okno: Through Day 180
Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment
Through Day 180
Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure
Časové okno: Through Day 180
Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).
Through Day 180
Time to In-hospital Worsening Heart Failure Through Day 5
Časové okno: Through Day 5
Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.
Through Day 5
Use of Loop Diuretic and Vasoactive Agents
Časové okno: Through Day 5
Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5
Through Day 5
Change From Baseline in Cardio-renal Biomarkers
Časové okno: Day 2 and Day 5
Day 2 and Day 5
Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.
Časové okno: For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.
To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.
For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Novartis Pharmaceuticals

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

12. března 2014

Primární dokončení (Aktuální)

27. března 2017

Dokončení studie (Aktuální)

16. června 2017

Termíny zápisu do studia

První předloženo

20. listopadu 2013

První předloženo, které splnilo kritéria kontroly kvality

9. prosince 2013

První zveřejněno (Odhad)

11. prosince 2013

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

2. srpna 2019

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

12. června 2019

Naposledy ověřeno

1. června 2019

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • CRLX030A2302

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Akutní srdeční selhání

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Kenya

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

3
Předplatit